ArticleBiology2026
NARVGA: A Hybrid Framework Integrating Matrix Factorisation and Adversarial Graph Learning for circRNA-Disease Association Prediction.
Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Circular RNAs (circRNAs) participate in gene regulation and disease progression, but experimental mapping of circRNA-disease associations (CDAs) remains costly and incomplete. We developed NARVGA, a hybrid prediction framework that combines non-negative matrix factorisation (NMF) with an adversarially regularised variational graph autoencoder (ARVGA). Functional, semantic and Gaussian interaction-profile kernel similarities are integrated; K-means-derived co-membership graphs reduce diffuse similarity connections; ARVGA learns nonlinear topological embeddings; and NMF captures complementary low-rank association patterns. An Extra Trees classifier then scores candidate circRNA-disease pairs. In the original transductive stratified five-fold benchmark on CircR2Disease, NARVGA achieved an area under the receiver operating characteristic curve (AUC) of 0.9868, an area under the precision-recall curve (AUPR) of 0.9887, 94.32% accuracy and a 94.44% F1-score. Ablation analysis identified cluster sparsification as the largest individual contributor, with additional gains from adversarial regularisation and low-rank augmentation. Without task-specific retuning, the model obtained AUCs of 0.9503 on LncRNADisease and 0.9700 on HMDDv4. Performance was stable across GCN depths and cluster settings, and 19 of the 20 highest-ranked hepatocellular carcinoma candidates had supporting published evidence. NARVGA provides a within-network prioritisation tool for RNA-disease association studies, although prospective validation, hard-negative assessment and independent-cohort testing remain necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.